NEW YORK (360Dx) – Vermillion said today its Aspira Labs subsidiary has entered into an agreement with Blue Cross Blue Shield of Louisiana for coverage of its OVA1 ovarian cancer test.
BCBC of Louisiana covers around 1.45 million lives in the state. The agreement follows previous decisions by Louisiana TriCare, Medicare, and Medicaid plans to cover OVA1.
According to Vermillion, OVA1 is now covered for more than 82 percent of the state's population. More than 97 million lives are contracted or have a positive policy determination for OVA1 nationwide.